Product

SARS-CoV-2 rS/Matrix-M1 Adjuvant

Aliases

Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), NVX-CoV2373, SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)

2 clinical trials

1 indication

Indication

COVID-19

Clinical trial

A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)

Status: Completed, Estimated PCD: 2023-04-10

Clinical trial

A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age

Status: Active (not recruiting), Estimated PCD: 2023-11-13